Hsiang-Hsi Ling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hsiang-Hsi Ling has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Cheng-Wei Lin
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
3 shared publications Chih-Chia Kuo
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
2 shared publications- Aaron D. Viny
Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
1 shared publication Ajay K. Saw
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publicationBo-Xing Lin
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
1 shared publicationCheng-Hsun Chen
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
1 shared publication
Latest Publications
- 22 June 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (7) , 1513-1528
Mediator subunit MED4 enforces metastatic dormancy in breast cancer
Long-term survival in breast cancer is often limited by metastatic recurrence arising from disseminated cancer cells that persist in a dormant state. The mechanisms that enable these dormant cells to survive and subsequently reawaken remain incompletely understood. Here an unbiased genome-scale genetic screen identified Med4 as a cancer cell-intrinsic gatekeeper in metastatic reactivation. Correspondingly, MED4 haploinsufficiency was found to be prevalent in metastatic breast cancer and associated with poorer clinical outcomes. Syngeneic mouse metastasis models revealed that MED4 enforces metastatic dormancy. Mechanistically, and unexpectedly given the canonical role of the Mediator complex in transcriptional activation, MED4 suppresses enhancer priming (H3K4me1) and activation (H3K27ac). Loss of a single Med4 allele disrupts enhancer poise, leading to extracellular matrix remodelling and integrin-mediated mechanotransduction programmes that ultimately drive metastatic outgrowth. Together, these findings establish MED4 as a key regulator of breast cancer cell dormancy and nominate MED4 haploinsufficiency as a potential predictive biomarker for patients at high risk of metastatic relapse.
- 22 June 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (7) , 1513-1528
Mediator subunit MED4 enforces metastatic dormancy in breast cancer
Long-term survival in breast cancer is often limited by metastatic recurrence arising from disseminated cancer cells that persist in a dormant state. The mechanisms that enable these dormant cells to survive and subsequently reawaken remain incompletely understood. Here an unbiased genome-scale genetic screen identified Med4 as a cancer cell-intrinsic gatekeeper in metastatic reactivation. Correspondingly, MED4 haploinsufficiency was found to be prevalent in metastatic breast cancer and associated with poorer clinical outcomes. Syngeneic mouse metastasis models revealed that MED4 enforces metastatic dormancy. Mechanistically, and unexpectedly given the canonical role of the Mediator complex in transcriptional activation, MED4 suppresses enhancer priming (H3K4me1) and activation (H3K27ac). Loss of a single Med4 allele disrupts enhancer poise, leading to extracellular matrix remodelling and integrin-mediated mechanotransduction programmes that ultimately drive metastatic outgrowth. Together, these findings establish MED4 as a key regulator of breast cancer cell dormancy and nominate MED4 haploinsufficiency as a potential predictive biomarker for patients at high risk of metastatic relapse.
- Open Access
- 1 January 2019
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (9) , 2526-2540
Metastatic Colorectal Cancer Rewrites Metabolic Program Through a Glut3-YAP-dependent Signaling Circuit
Rationale: Cancer cells reprogram cellular metabolism to fulfill their needs for rapid growth and metastasis. However, the mechanism controlling this reprogramming is poorly understood. We searched for upregulated signaling in metastatic colorectal cancer and investigated the mechanism by which Glut3 promotes tumor metastasis.
- 1 January 2019
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (9) , 2526-2540
Open AccessMetastatic Colorectal Cancer Rewrites Metabolic Program Through a Glut3-YAP-dependent Signaling Circuit
Rationale: Cancer cells reprogram cellular metabolism to fulfill their needs for rapid growth and metastasis. However, the mechanism controlling this reprogramming is poorly understood. We searched for upregulated signaling in metastatic colorectal cancer and investigated the mechanism by which Glut3 promotes tumor metastasis.
- 2 January 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (6) , 4972-4980
Activation of fibroblasts by nicotine promotes the epithelial‐mesenchymal transition and motility of breast cancer cells
The tumor microenvironment plays an important role in tumor initiation and progression. It is well documented that nicotine participates in cigarette smoking‐related malignancies. Previous studies focused on the effects of nicotine on tumor cells; however, the role of the microenvironment in nicotine‐mediated tumorigenesis is poorly understood. Herein, we investigated the effect and molecular mechanism of nicotine on fibroblasts and its contribution to breast cancer. We found that nicotine induced the epithelial‐mesenchymal transition (EMT) of breast cancer cells and promoted activation of fibroblasts. Interestingly, conditioned medium from nicotine‐activated fibroblasts (Nic–CM) had a greater impact on promoting the EMT and migratory capability toward cancer cells than did treatment with nicotine alone. Production of connective tissue growth factor (CTGF) and transforming growth factor (TGF)‐β by nicotine‐treated fibroblasts was demonstrated to be crucial for promoting the EMT and cancer cell migration, and blocking of CTGF and TGF‐β in Nic‐CM‐suppressed tumor motility. Moreover, nicotine induced expressions of CTGF, and TGF‐β in fibroblasts as identified through α7 nicotinic acetylcholine receptor (nAChR)‐dependent activation of the AKT/TAZ signaling mechanism. Together, our data showed for the first time that activation of fibroblasts is largely responsible for accelerating smoking‐mediated breast cancer progression.
- 2 January 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (6) , 4972-4980
Activation of fibroblasts by nicotine promotes the epithelial‐mesenchymal transition and motility of breast cancer cells
The tumor microenvironment plays an important role in tumor initiation and progression. It is well documented that nicotine participates in cigarette smoking‐related malignancies. Previous studies focused on the effects of nicotine on tumor cells; however, the role of the microenvironment in nicotine‐mediated tumorigenesis is poorly understood. Herein, we investigated the effect and molecular mechanism of nicotine on fibroblasts and its contribution to breast cancer. We found that nicotine induced the epithelial‐mesenchymal transition (EMT) of breast cancer cells and promoted activation of fibroblasts. Interestingly, conditioned medium from nicotine‐activated fibroblasts (Nic–CM) had a greater impact on promoting the EMT and migratory capability toward cancer cells than did treatment with nicotine alone. Production of connective tissue growth factor (CTGF) and transforming growth factor (TGF)‐β by nicotine‐treated fibroblasts was demonstrated to be crucial for promoting the EMT and cancer cell migration, and blocking of CTGF and TGF‐β in Nic‐CM‐suppressed tumor motility. Moreover, nicotine induced expressions of CTGF, and TGF‐β in fibroblasts as identified through α7 nicotinic acetylcholine receptor (nAChR)‐dependent activation of the AKT/TAZ signaling mechanism. Together, our data showed for the first time that activation of fibroblasts is largely responsible for accelerating smoking‐mediated breast cancer progression.
- 1 January 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 350 (1) , 218-225
Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer
- 1 January 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 350 (1) , 218-225
Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer